A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Trial Profile

A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-066
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Sep 2017 Results of a pooled post-hoc analysis from CheckMate 069, CheckMate 066, and CheckMate 067 studies, presented at the 42nd European Society for Medical Oncology Congress
    • 11 Aug 2017 Results of CA209003, CA209037 and CA209066 studies, published in the Journal of Clinical Pharmacology.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top